Characterizing the folding core of the cyclophilin A - cyclosporin A
  complex I: hydrogen exchange data and rigidity analysis by Heal, J. W. et al.
i
i
“CypA˙Paper˙1” — 2018/9/12 — 8:23 — page 1 — #1 i
i
i
i
i
i
Biophysical Journal Volume: 00 Month Year 1–6 1
Characterizing the folding core of the cyclophilin A — cyclosporin A
complex I: hydrogen exchange data and rigidity analysis
J. W. Heal∗†, R. A. Ro¨mer§, C. A. Blindauer‡ and R. B. Freedman¶
†MOAC Doctoral Training Centre and Institute of Advanced Study, ‡Department of Chemistry,
§Department of Physics and Centre for Scientific Computing, and ¶School of Life Sciences,
University of Warwick, Coventry, CV4 7AL, UK
Abstract
The determination of a “folding core” can help to provide insight into the structure, flexibility, mobility and
dynamics, and hence, ultimately, function of a protein — a central concern of structural biology. Changes in the
folding core upon ligand binding are of particular interest because they may be relevant to drug-induced functional
changes. Cyclophilin A is a multi-functional ligand-binding protein and a significant drug target. It acts principally
as an enzyme during protein folding, but also as the primary binding partner for the immunosuppressant drug
cyclosporin A (CsA). Here, we have used hydrogen-deuterium exchange (HDX) NMR spectroscopy to determine
the folding core of the CypA-CsA complex. We also use the rapid computational tool of rigidity analysis, imple-
mented in First, to determine a theoretical folding core of the complex. In addition we generate a theoretical
folding core for the unbound protein and compare this with previously published HDX data. The First method
gives a good prediction of the HDX folding core, but we find that it is not yet sufficiently sensitive to predict the
effects of ligand binding on CypA.
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INTRODUCTION
The protein folding problem has been a prevalent ques-
tion during the past 50 years as the emerging protein
structure crucially determines flexibility, mobility and,
ultimately, function (1). The two principal competing
theories on how protein folding initiates are diffusion-
collision (2) and nucleation-condensation (3). Indeed, it
may well be that both are valid depending on which
protein is being investigated (4). Intuitively, residues
which “collapse early during folding” (5), might be par-
ticularly important to the overall folding process and
are usually referred to as defining a folding core. How-
ever, this set of residues is difficult to ascertain precisely.
One way of defining a folding core experimentally is
through Φ-value analysis (6). This approach focuses on
the folding process by using point mutations to deter-
mine the impact of particular residues on the energy
of the transition state in a one-step folding process.
An alternative is to study the dynamics of the folded
structure through hydrogen-deuterium exchange (HDX)
NMR experiments. For the examples of barnase and
chymotrypsin inhibitor 2, it has been shown that the
two definitions are consistent in that slowly exchanging
residues in HDX have high Φ-values (7).
We have selected cyclophilin A (CypA), a multi-
functional 18 kDa protein with 165 residues, as the
basis protein for our study since it is large enough to
exhibit complex folding behaviour while at the same
time it is readily investigated by HDX. Furthermore,
among the large class of ligand-binding proteins, it is
known to bind strongly to the immunosuppressant drug
cyclosporin A (CsA) (8–10), with dissociation constant
KD = 46 nM (11). CypA acts as a peptidyl-prolyl cis-
trans isomerase in addition to performing other roles
when binding to different molecules such as the HIV-1
capsid protein (12–14). The structure of the CypA-CsA
complex is shown in Figure 1 with the binding site
residues highlighted (15). Most commonly used to sup-
press organ rejection following a transplant, CsA has
also been administered to treat ulcerative colitis, cardiac
disease and a number of autoimmune diseases (17–19).
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Figure 1: (a) Sphere and (b) cartoon representation
of the CypA-CsA complex and the CypA binding site
(using PDB structure 1CWA and the PyMOL visual-
izer (16)). CsA is indicated in blue and CypA in green.
The 15 residues of CypA which have a heavy (non-
hydrogen) atom within 4 A˚ of the atoms in CsA are
colored red.
It is the CypA-CsA complex which binds to and inhibits
the T-cell activator calcineurin (CN) and thus has an
immunosuppressant effect (20, 21).
Here, we experimentally study the HDX behaviour
of unbound CypA and also its complex with CsA. Using
these HDX data, we establish the resulting folding cores.
Our results compare very well with previously published
HDX data on unbound CypA (22) and also elucidate
the effect of ligand binding in the CypA-CsA complex.
NMR has been used to solve the structure of CypA
(10) as well as the CypA-CsA complex (8, 9). HDX
experiments on unbound CypA have previously been
conducted (22) but the CypA-CsA complex has not
previously been studied in this way.
Establishing folding cores through Φ-value analysis
or HDX provides valuable insight into protein folding
and dynamics, but also involves extensive experimental
work. For this reason, the prediction of HDX folding
cores through rapid computational methods is of ongo-
ing interest (4, 23–27). One method for predicting HDX
folding cores uses rigidity analysis and is implemented in
the First software package (4, 23). Having found the
HDX folding core in our experiments, we next apply
First to unbound CypA and to the CypA-CsA com-
plex. We compare the resulting predicted folding cores
with the HDX results.
MATERIALS AND METHODS
Protein expression and purification
A derivative of the pQE-70 plasmid encoding for human
CypA was expressed in E. coli (JM109, New England
BioLabs) grown at 37◦C in minimal medium containing
1 g/L (15NH4)2SO4 (Cambridge Isotope Laboratories).
When the growth cultures reached an optical density
of 0.5 at 600 nm, protein expression was induced with
1 mM isopropyl-β-D-thiogalactopyranoside (IPTG).
Cells were harvested after overnight growth during
which selection pressure was maintained by adding
0.1 mg/mL ampicilin. Cell pellets were resuspended in
20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES) buffer at pH = 6.5 and then stored at
−20◦C. Frozen cells were thawed, sonicated and then
centrifuged, after which the resulting supernatant was
loaded onto a 10 mL Source 30S column (from GE
Healthcare) for cation exchange using 20 mM HEPES
buffer at pH = 6.5 and a concentration gradient of
0− 150 mM NaCl. Eluted fractions of CypA were dial-
ysed overnight against 10 mM ammonium acetate buffer
at pH = 6.5 before being concentrated and lyophilised.
NMR assignment and HDX experiments
For sequential assignment, lyophilised protein was
resuspended in NMR buffer containing 4.2 mM
NaH2PO4, 15.8 mM Na2HPO4 and 150 mM NaCl at pH
6.5. 2D [1H,15N] HSQC and 3D [1H, 15N, 1H] TOCSY-
HSQC and NOESY-HSQC data were acquired on a
Bruker AV III 600 spectrometer operating at 600.13
MHz for 1H and 60.81 MHz for 15N. 2D data were
acquired with 16 scans, 2048 datapoints in F2 and
128 increments in F1, and Fourier transformed with
2048×512 datapoints over spectral widths of 16 ppm in
the 1H dimension (F2) and 42 ppm in the 15N dimen-
sion (F1). 3D data were acquired with 8 or 16 scans and
2048×40×160 datapoints in F3, F2 and F1, respectively,
and transformed with 2048×64×512 datapoints. Spec-
tral widths were 16 ppm in the 1H dimensions (F3, F1),
and 38 ppm in the 15N dimension (F2). 2D HSQC data
for the HDX experiments were acquired on a Bruker AV
II 700 spectrometer, equipped with a TCI cryoprobe,
operating at 700.24 MHz for 1H and 70.96 for 15N. The
lyophilised protein was resuspended in NMR buffer as
above, but made up in 99.9% D2O (Sigma-Aldrich).
For the CypA-CsA sample, each spectrum was acquired
with four scans, 2048 points in F2, and 64 increments in
F1, and Fourier transformed with 2048×256 datapoints.
The spectral widths were 16 ppm and 42 ppm in the 1H
and 15N dimensions, respectively. In all cases, chemical
shifts δ were referenced to the residual HDO peak (28).
Data were acquired and processed using Topspin ver-
sion 2.1 (Bruker) and analyzed using Sparky version
3.1 (29).
Rigidity analysis with First
Protein rigidity analysis is a computational method
which rapidly identifies rigid and flexible regions in a
Biophysical Journal 00(00) 1–6
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protein crystal structure (30, 31). The structure is con-
sidered as a molecular framework in which bond lengths
and angles are considered fixed while dihedral angles are
permitted to vary. Atomic degrees of freedom are then
matched against bonding constraints (31–37). Covalent
bonds, polar interactions (including hydrogen bonds
and salt bridges), and hydrophobic tethers can all be
included as bonding constraints. The output of the algo-
rithm is a division of the structure into rigid clusters and
flexible regions, known as a rigid cluster decomposition
(RCD). The RCD clearly depends on the constraints
present in the bond network, the strength and location
of which are determined solely from the geometry of
the input structure. A systematic removal of hydrogen
bonds in order from weakest to strongest leads to a loss
in rigidity which we can relate to the unfolding of the
protein (30). This is referred to as a rigidity dilution
(RD). The pattern of rigidity loss can be used to gain
insight into structural and functional properties of the
protein (30, 38, 39). Indeed, RDs have previously been
used to predict the HDX folding core for a number of
proteins (4, 23) not including CypA.
The X-ray crystal structure 1CWA of the CypA-CsA
complex was downloaded from the Protein Data Bank
(PDB) (40). Crystal water molecules were removed
before the reduce software (41) was used to add the
hydrogen atoms and to flip side chains of Asn, Gln
and His residues where necessary. For simulations of
the unbound protein, CsA was deleted from the struc-
ture manually using PyMOL (16), which was used for
all molecular visualization. We note that the unbound
structure for CypA is highly similar to the bound struc-
ture. Indeed, the backbone of 1CWA aligns with a dif-
ferent structure of the unbound protein (1W8V) with
an RMSD of 0.26 A˚.
The strength of each hydrogen bond, measured in
kcal/mol, was calculated as a function of the geome-
try of the donor, hydrogen and acceptor atoms using
the highly distance- and angle-dependent Mayo poten-
tial (38, 42). Only hydrogen bonds with a bond energy
more negative than the energy cutoff parameter Ecut are
included in the network. During an RD, Ecut is lowered
causing some hydrogen bonds to be excluded from the
network. Rigidity dilution involves systematically low-
ering Ecut and re-evaluating the RCD. Rigidity analysis
was conducted using First version 6.1 (43).
RESULTS AND DISCUSSION
Characterization of CypA and sequential assignment
Purified recombinant CypA was characterized using
mass spectrometry and circular dichroism spectroscopy,
confirming that the protein had the correct mass
and secondary structure (Supporting Material). When
CypA binds to CsA, the change in environment of the
Trp121 residue results in enhanced fluorescence (with an
excitation wavelength of 290 nm and a peak of emission
at 340 nm) (44, 45). We observed enhanced fluorescence
during a titration of CsA into CypA, which plateaued
at a 1:1 concentration ratio (Supporting Material). This
confirmed ligand binding.
Employing 3D TOCSY- and NOESY-HSQC data,
and with the aid of previously published assignments
for the CypA-CsA complex under different conditions
(8, 10), we have assigned 147 of the 159 non-proline
residues of the protein in its unbound state as well as
in complex with CsA.
The unassigned residues include residues 1 – 4,
which make up the flexible N-terminus. In Figure 2, we
show the assigned HSQC spectrum for the CypA-CsA
complex. Full lists of backbone N-H assignments for this
spectrum and for the unbound protein can be found in
the Supporting Material.
The HDX folding cores
Figure 3 shows the HSQC spectrum of the CypA-CsA
complex alongside spectra recorded 10, 110 and 4270
minutes (71 hours and 10 minutes) after initiating HDX.
We define the set of residues for which a corresponding
backbone amide signal remains in the HSQC spectrum
after 110 minutes to be the experimentally determined
HDX folding core of the complex. These residues are
listed in Table 1 and also indicated in Figure 4 (a) and
(b).
The published HDX experiments on unbound CypA
resulted in a classification of CypA residues in terms of
their exchange rates, kex (22). Twelve residues, includ-
ing the proline residues, were not categorized since they
were not identified in the HSQC spectrum. We also car-
ried out HDX experiments on the unbound protein, and
our data, shown in the Supporting Material, were in
agreement with the previously published result (22).
Here we have drawn on the exchange rates deter-
mined in (22) and defined the residues with kex < 10
−2
min−1 as the folding core of the unbound protein, a def-
inition congruent with that applied to our dataset for
the CypA-CsA complex (see above). According to this
approach, the HDX folding core for unbound CypA has
73 residues.
We find that the HDX folding core does not change
dramatically upon ligand binding. Its size increases from
73 to 80 residues. This is due to the ten residues, high-
lighted in Table 1, which are slowly exchanging in the
presence of the CsA ligand but not part of the HDX
folding core for unbound CypA. However, there are also
three assigned residues — G18, A101 and I158 — which
are part of the ’unbound’ folding core of (22) but are
Biophysical Journal 00(00) 1–6
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Figure 2: HSQC spectrum of the CypA-CsA complex. Blue contour lines show signal intensity, and assigned back-
bone N-H cross peaks are labeled. Chemical shift frequencies δ(1H) and δ(15N) are given in parts per million
(ppm).
Table 1: The residues of the HDX folding core for
the CypA-CsA complex. Underlined residues are slowly
exchanging only in the presence of the ligand.
CypA-CsA HDX folding core residues
V6, F7, F8, D9, I10, A11, V12, E15, L17, V20, S21,
F22, E23, L24, F25, A26, V29, K31, T32, A33, E34,
N35, F36, R37, A38, L39, S40, T41, Y48, S51, F53,
H54, R55, I57, F60, M61, Q63, G64, K76, I78, E86,
N87, F88, I89, L90, G96, I97, L98, S99, M100, N108,
F112, F113, I114, C115, T116, A117, T119, L122,
D123, K125, V127, V128, F129, G130, K131, V132,
K133, I138, V139, E140, A141, M142, E143, F145,
T157, A159, D160, G162
no longer part of the ’bound’ folding core. This slight
increase in folding core size is consistent with the expec-
tation that the presence of a ligand is likely to shield
certain residues from the surface of the protein. Eight of
the highlighted residues belong to flexible regions which
are proximal to the binding site. Hence those changes
are consistent with a restricted flexibility of the unstruc-
tured regions near the binding site in the presence of the
ligand. The other two residues in the set, S21 and H54,
are located in β-strands. We note that these residues
are surrounded by folding core residues (V20, F22, F53,
R55) and so it is somewhat unexpected that these are
not part of the folding core for the unbound protein.
That they vanish earlier than expected from the HDX
experiments on the unbound protein may be due to the
inherent low signal intensity in these experiments.
The First folding cores
We then simulated RDs by systematically lowering Ecut,
i.e. removing the hydrogen bonds in order of strength
Biophysical Journal 00(00) 1–6
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Figure 3: (a) HSQC spectrum of the CypA-CsA complex as in Figure 2. Following initiation of HDX, spectra were
recorded after an elapsed time of, among others, (b) 10 minutes, (c) 110 minutes and (d) 4270 minutes. In each
spectrum, N-H cross peaks are shown as contour lines, representing signal intensity. Chemical shifts δ(1H) and
δ(15N) are given in ppm.
from weakest to strongest (38). We used First to gen-
erate an RCD each time a hydrogen bond was removed.
In a 1D representation of an RCD, each residue in the
primary structure is labelled as being rigid or flexible
depending on the rigidity of its Cα atom. We show rigid
residues as blocks which are colored according to their
rigid cluster membership.
We visualize the pattern of rigidity loss during RDs
by plotting the 1D representation of the RCD each time
this changes. Such plots for the CypA-CsA complex
and the unbound CypA are given in Figure 5. When
|Ecut| is small, the protein is largely rigid and many of
the residues are represented as blocks. As Ecut becomes
more negative, i.e. as stronger bonds are excluded from
the bond network, more residues become flexible. In
both of the RD plots there is a clear and abrupt tran-
sition from the largely rigid state to the largely flex-
ible state, consistent with the first-order rigidity loss
expected for a predominantly β-sheet protein (38). The
lowest line in the RD plot where at least three residues of
two or more secondary structures (as determined using
the DSSP algorithm (46)) are part of the same rigid
cluster determines the First folding core (4, 23, 47, 48).
We refer to the Ecut corresponding to this line as the
folding core energy, Efc. For unbound CypA, Efc =
−1.263 kcal/mol and for the CypA-CsA complex, Efc
= −1.452 kcal/mol. That the CypA-CsA complex has
a lower Efc suggests that ligand binding confers stabil-
ity on the complex, as more bonds need to be broken
in order to render the protein mostly flexible (48). The
residues that are mutually rigid in the RCD evaluated
at Efc, colored red in Figure 5, form the First folding
core.
Biophysical Journal 00(00) 1–6
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Figure 4: The HDX folding cores (blue) are given along with the First folding cores (red) for (a) the CypA-CsA
complex and (b) unbound CypA. The residue numbers along the protein backbone are indicated, with thin vertical
lines added every ten residues for clarity. Only the residues which are part of the folding cores are colored.
W
ed M
ay 25 14:44:57 2011 
H-bond
number E <r> 1 10 20 30 40 50 60 70 80 90
100
110
120
130
140
150
160 5
All 248 Hbonds
 186 -0.076  2.439 A C M 90  S  87  
 153 -0.654  2.421 A C S 108  M 83  
 150 -0.777  2.419 A C M 68  S  66  
 139 -1.062  2.414 A C M126  M122 
 131 -1.263  2.411 A C M 27  S   3  
 125 -1.452  2.408 A C M146  M143 
 123 -1.530  2.408 A C M102  M 11  
 112 -2.090  2.403 A C M123  M120 
 110 -2.096  2.403 A C S  51  M 48  
 109 -2.146  2.402 A C M143  M139 
 107 -2.226  2.401 A C M 84  S  84  
 105 -2.307  2.400 A C M139  M135 
  79 -3.242  2.390 A C M 39  M 35  
  75 -3.407  2.389 A C M 60  M 57  
  73 -3.499  2.388 A C M 28  M 25  
  61 -3.830  2.385 A C M 35  M 31  
Blue:donor Red:acceptor M:main-chain   S:side-chain   W:water   H:hetero-atom 1CWA_FH.ps
-0 076 
-0 654 
-0 777 
- 1 062 
- 1 263 
- 1 452 
- 1.530 
- . 90 
-  . 96 
-  .146 
-  .226 
-  .307 
- 3.242 
- 3.407 
- 3.499 
- 3. 30 
 0.000 
 Ecut 
W
ed Jul  6 17:30:50 2011 
H-bond
number E <r> 1 10 20 30 40 50 60 70 80 90
100
110
120
130
140
150
160
All 243 Hbonds
 182 -0.076  2.440 A M 90  S  87  
 155 -0.493  2.424 A M 72  S  66  
 154 -0.495  2.424 A M106  S  85  
 153 -0.521  2.423 A M 70  M 66  
 149 -0.654  2.420 A S 108  M 83  
 146 -0.777  2.419 A M 68  S  66  
 135 -1.062  2.414 A M126  M122 
 127 -1.263  2.411 A M 27  S   3  
 125 -1.376  2.409 A M165  M  5  
 123 -1.421  2.408 A M 61  M 57  
 121 -1.452  2.407 A M146  M143 
 109 -2.090  2.403 A M123  M120 
 107 -2.096  2.402 A S  51  M 48  
 106 -2.146  2.401 A M143  M139 
 104 -2.226  2.400 A M 84  S  84  
 102 -2.307  2.399 A M139  M135 
  79 -3.242  2.390 A M 39  M 35  
  75 -3.407  2.389 A M 60  M 57  
  73 -3.499  2.388 A M 28  M 25  
  61 -3.830  2.385 A M 35  M 31  
Blue:donor Red:acceptor M:main-chain   S:side-chain   W:water   H:hetero-atom 1CWA_FH_U.ps
-0.076 
-0.654 
-0.777 
- 1.062 
- 1.263 
- 1.452 
- . 90 
-  . 96 
-  .146 
-  .226 
-  .307 
- 3.242 
- 3.407 
- 3.499 
- 3. 30 
 0.000 
-0.493 
-0.495 
-0.521 
- 1.376 
- 1.421 
 Ecut 
1 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
110 
120 
130 
140 
150 
160 
1 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
110 
120 
130 
140 
150 
160 
Figure 5: RD plots of (a) the CypA-CsA complex, and
(b) unbound CypA. The RCD is shown at different
values of Ecut. The units of Ecut are kcal/mol. Rigid
residues are shown as thick colored blocks and flexible
regions as thin horizontal black lines. Residues which
are mutually rigid are shown in the same color. The
line representing the First folding core in each case is
indicated with an arrow.
Comparison of First and HDX folding cores
Figure 4 allows us to compare the HDX and First fold-
ing cores along the primary structure of the CypA-CsA
complex and unbound CypA. Residues which form part
of the folding cores are represented as colored blocks.
In both cases, the First folding cores largely overlap
with the HDX folding cores. The small changes which
do occur upon ligand binding in the HDX folding cores
are not very well captured in the two First folding
cores. Rather, these differ only between residues 133 and
155, whereas the HDX folding cores remain largely unaf-
fected in this region. Notably, the First folding core for
the CypA-CsA complex is smaller than for the unbound
protein. This contrasts with our expectation and exper-
imental finding as given above, where we show that the
HDX folding core increases in size upon ligand binding.
This highlights a problem with a theoretical method
that only uses First. Ligand binding to the surface of
CypA causes the binding site residues to become buried
where before they were exposed, which may affect their
HDX exchange rates. This effect is not modelled in
First, where we merely consider the hydrogen bond
network of the initial, static crystal structure.
In Figure 6 the HDX and First folding cores are
shown superimposed onto the structure 1CWA before
and after the removal of the ligand. We see that despite
the issues addressed above, theoretically and experi-
mentally determined folding cores agree reasonably well
for most of the residues. The helix in the foreground of
each image shows a marked difference when the ligand
is removed, caused by the difference in First folding
core between residues 133 and 155. Residues 87 – 89
Biophysical Journal 00(00) 1–6
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a b 
Figure 6: The HDX and First folding cores for (a) the CypA-CsA complex and (b) unbound CypA indicated in
the cartoon representation. Residues are colored purple when they are part of both folding cores, blue when they
belong to the HDX folding core only, red when part of the First folding core only or green when not part of either
folding core. In (a), CsA is colored black and the arrow indicates the loop region containing residues 87 – 89.
form part of the loop indicated by the arrow in Fig-
ure 6(a), and are only part of the HDX folding core in
the presence of CsA.
CONCLUSION
The experimental HDX folding core for the CypA-CsA
complex is highly similar to the folding core for the
unbound protein, albeit with a small number of addi-
tional residues. This small change is consistent with pre-
vious observations of only subtle conformational change
in CypA upon ligand binding (10, 49). The First fold-
ing cores differ more substantially. Ligand binding con-
fers rigidity upon the structure but alters the pattern
of rigidity loss so that the First folding core in fact
decreases in size. In both cases, the First folding core
is a reasonable match for the HDX folding core, in agree-
ment with previous folding core predictions using First
(4). The First folding core is defined by the RCD at
Efc, a value which decreases upon ligand binding. This
means that when the folding cores are compared for the
protein before and after ligand removal, we are compar-
ing RCDs at different Ecut. As a result there may be
more constraints present in the unbound protein Ecut
than for the complex, resulting in the unlikely predic-
tion of a larger folding core in the absence of a ligand.
First is a rapid tool to implement and this study com-
plements previous studies which demonstrate its utility
for folding core prediction (4, 23, 47, 48). Neverthe-
less, our work also shows that the First-based folding
core predictions are not yet accurate or sensitive enough
to capture the impact of ligand binding for CypA. For
the purpose of predicting subtle effects of ligand bind-
ing, just analyzing patterns of rigidity as done through
First appears insufficient. The trade-off between, on
one hand, rapid computation as achieved with First
and, on the other hand, the necessary accuracy of fold-
ing core prediction needs to be more finely balanced. In
the related Ref. (50), we show that when taking into
account not only the rigidity of a protein, but also its
propensity for motion, improved theoretical predictions
for folding cores can be made with greater sensitivity
and specificity.
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Supporting Material
Characterizing the folding core of the cyclophilin A — cyclosporin A complex I: hydrogen exchange
data and rigidity analysis
J. W. Heal, R. A. Ro¨mer, C. A. Blindauer and R. B. Freedman
1 Mass spectrometry and circular dichroism spectroscopy
To estimate the secondary structure composition for purified CypA in order to verify that it was correctly folded,
the far-UV CD spectrum of CypA was measured at 25◦C using a Jasco J-815 CD spectropolarimeter. The resulting
spectrum is shown in Figure S1. CD spectra were recorded for protein samples of 0.1 mg/mL in 5 mM sodium
phosphate, pH 7.3 unless otherwise stated. Small volumes of concentrated purified protein were diluted in sodium
phosphate buffer and the resulting concentration confirmed by measuring A280. Data points were collected during
far-UV scans between 180 nm and 260 nm at 1 nm intervals. A baseline spectrum was recorded in the same way
for a sample containing buffer only. To generate Figure S1, 16 scans were collected at 100 nm/min in continuous
scanning mode, and the average CD signal minus the average baseline signal was plotted. We show the data col-
lected between 190 nm and 240 nm at 1 nm intervals. The data was analysed with Dichroweb, using the reference
database SP175 to calculate the proportional secondary structure composition of CypA. Our protein sample was
determined to be 18 % helix and 33 % sheet. We compared this with the results of the DSSP algorithm applied to
five X-ray crystal structures in the PDB. The average composition of these structures was 13 % α-helix and 32 %
β-sheet.
2 Fluorescence
When CsA binds to CypA, Trp121 becomes shielded from the solvent and its fluorescence increases as a result
(11, 44). CsA was titrated into a solution of CypA and fluorescence spectroscopy was used to monitor the change
in tryptophan fluorescence. The experiment was conducted using a Photon Technology International fluorimeter.
A stock solution of CypA (65 µM) was diluted 1 mL in 50 mM TRIS buffer at pH 7.3 so that the final CypA
concentration was 4.5 µM. CsA was stored in ethanol at a concentration of 1.0 mM. A stock solution of 0.1 mM
CsA for the titration was made by diluting this ten-fold in TRIS buffer. Each titre consisted of 10 µL of CsA stock,
and so increased the total concentration of CsA in the fluorescence sample by approximately 1 µM. After each
increment in [CsA] the sample was mixed using a pipette. The emission spectra were recorded at 1 nm intervals
between 300 nm and 400 nm, using an excitation wavelength of 290 nm. The average fluorescence emission of three
scans was recorded for each wavelength, using a slit width of 2 nm. Two baselines were recorded, for samples con-
taining TRIS buffer only and 5 µM CsA in TRIS buffer. There was no significant difference between the baselines
(data not shown). Baseline adjusted fluorescence emission spectra for CypA with various concentrations of CsA
are shown in Figure S2. The key shows the concentration fraction [CsA]/[CypA]. We observe a steady increase in
fluorescence with increasing [CsA] until [CsA]/[CypA] = 1. After this point is reached, adding more CsA does not
enhance fluorescence.
3 HDX results for unbound CypA
For unbound CypA, we increased the number of scans recorded for each spectrum from 4 to 16 in response to a lower
yield in order to maximise the signal to noise ratio. The earliest usable HSQC spectrum was completed 53 minutes
after adding D2O to the protein sample, and the subsequent spectra were therefore recorded less frequently than
with the CypA-CsA experiments. Figure S3 shows the full HSQC spectrum, along with spectra taken at different
time intervals following the initiation of HDX. Spectrum numbers 1, 4 and 22 are shown, recorded after 53, 113
and 4349 minutes respectively.
4 N-H assignment tables
Table S1 gives the chemical shift assignments for each residue of unbound protein as well as the CypA-CsA complex.
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Table S1: Chemical shift assignment of CypA backbone 15N-1H pairs, for the unbound protein as well as the
CypA-CsA complex. Chemical shifts are given in ppm. Blank cells represent unassigned signals.
Residue
CypA only CypA-CsA
Residue
CypA only CypA-CsA
1H 15N 1H 15N 1H 15N 1H 15N
Thr5 8.78 115.02 8.76 115.03 Glu86 9.45 131.63 9.51 131.82
Val6 8.74 120.4 8.71 120.65 Asn87 7.05 106.84 7.04 106.78
Phe7 8.95 119.23 8.96 119.34 Phe88 8.33 113.02 8.32 112.9
Phe8 9.55 117.03 9.56 117.01 Ile89 8.3 119.89 8.29 119.85
Asp9 9.27 124.24 9.27 124.22 Leu90 7.74 117.28 7.75 117.2
Ile10 9.03 124.31 9.04 124.27 Lys91 8.07 119.05 8.07 119
Ala11 9.62 132.57 9.63 132.48 His92 10.7 122.57 10.58 122.33
Val12 8.93 118.47 8.94 118.31 Thr93 7.26 110.48 7.25 110.42
Asp13 9.85 131.09 9.86 131 Gly94 7.48 107.31 7.53 107.37
Gly14 8.55 101.75 8.56 101.63 Pro95 N/A N/A N/A N/A
Glu15 8.04 123.34 8.03 123.33 Gly96 9.27 110.31 9.25 110.7
Pro16 N/A N/A N/A N/A Ile97 6.76 121.49 6.77 121.31
Leu17 9.2 126.13 9.17 125.96 Leu98 7.87 128.89 7.81 129.95
Gly18 7.24 102.52 7.23 102.33 Ser99 8.28 118.81 7.94 119.4
Arg19 8.34 121.29 8.35 121.28 Met100 8.28 123.27
Val20 9.37 126.94 9.38 126.92 Ala101 7.99 125.97 8.22 126.95
Ser21 8.76 120.36 8.77 120.39 Asn102 8.11 113.4 7.68 113.59
Phe22 9.51 119.11 9.5 119.02 Ala103 8.77 123.37 9.18 121.03
Glu23 8.74 123.23 8.7 123.15 Gly104 8.18 109.38 8.24 107.71
Leu24 8.17 122.5 8.14 122.45 Pro105 N/A N/A N/A N/A
Phe25 8.82 124.75 8.87 124.77 Asn106 8.86 119.13 8.87 119.05
Ala26 8.43 129 8.46 129.05 Thr107 10.21 110.39 10.3 110.31
Asp27 8.97 114.09 8.99 113.99 Asn108 7.37 120.61 7.42 120.56
Lys28 7.53 118.08 7.53 118 Gly109 9.15 110.83 9.14 110.91
Val29 8.36 114.64 8.36 114.86 Ser110 8.76 117.15 8.77 117.12
Pro30 N/A N/A N/A N/A Gln111 8.37 124.52 8.41 124.79
Lys31 10.66 123.84 10.7 124.02 Phe112 8.05 117.86 8.15 118.29
Thr32 10.28 124.06 10.27 124.08 Phe113 9.8 116.5 9.83 115.02
Ala33 9.28 125.67 9.23 125.52 Ile114 9.02 118.07
Glu34 8.02 117.28 8.03 117.29 Cys115 9.59 125.52 9.49 124.78
Asn35 7.12 115.69 7.13 115.69 Thr116 8.95 115.72 9.04 115.71
Phe36 7.01 117.92 7.02 117.89 Ala117 7.61 122.32 7.58 122.41
Arg37 8.94 121.1 8.95 121.15 Lys118 8.69 119.87
Ala38 8.69 119.16 8.62 118.81 Thr119 7.61 120.21 7.37 118.3
Leu39 8.17 120.78 8.2 120.86 Glu120 9.09 124.63 9.06 124.65
Ser40 7.89 119.28 7.89 119.3 Trp121 7.25 117.92 7.3 118.3
Thr41 7.97 108.49 7.98 108.56 Leu122 7.01 120.05 7.05 120.72
Gly42 7.57 108.4 7.57 108.24 Asp123 7.59 122.24 7.56 122.37
Glu43 8.01 118.7 8.01 118.7 Gly124 9.53 111.33 9.57 111.14
Lys44 9.1 118.55 9.11 118.38 Lys125 7.74 115.68 7.57 114.75
Gly45 7.93 105.59 7.93 105.48 His126 7.61 120.21
Phe46 6.41 113.75 6.41 113.59 Val127 8.24 124.74
Gly47 7.75 104.7 7.72 104.61 Val128 9.47 133.07 9.38 132.94
Tyr48 6.88 113.79 6.86 113.89 Phe129 8.1 117.87 8.11 117.89
Lys49 8.47 124.92 8.48 124.84 Gly130 7.36 110.79 7.36 110.73
Gly50 9.48 117.9 9.52 117.97 Lys131 8.34 115.36 8.3 115.06
Ser51 8.38 116.5 8.4 116.58 Val132 9.03 124.26
Cys52 10.01 115.3 10.1 115.31 Lys133 9.47 131.87 9.44 131.73
Phe53 8.69 123.05 8.66 122.99 Glu134 7.53 118.49 7.53 118.5
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Residue
CypA only CypA-CsA
Residue
CypA only CypA-CsA
1H 15N 1H 15N 1H 15N 1H 15N
His54 7.56 119.88 7.52 119.7 Gly135
Arg55 7.04 123.14 6.87 124.3 Met136 8.85 122.66 8.86 122.66
Ile56 9.19 126.48 9.13 127.27 Asn137 9.05 114.4 8.91 114.42
Ile57 8.54 123.02 8.49 127.36 Ile138 7.64 124.28 7.64 124.24
Pro58 N/A N/A N/A N/A Val139 7.24 121.97 7.26 122.16
Gly59 9.73 114.24 9.85 114.11 Glu140 8.26 117.69 8.31 117.82
Phe60 8.17 119.37 8.1 119.19 Ala141 7.49 121.13 7.49 121.04
Met61 8.08 111.2 7.86 110.41 Met142 8.29 117.3 8.29 117.41
Cys62 8.47 114.88 Glu143 7.82 116.36 7.89 116.6
Gln63 8.72 127.99 9.33 127.5 Arg144 7.02 114.61 7.02 114.63
Gly64 7.36 110.79 7.48 110.77 Phe145 7.61 115.42 7.62 115.25
Gly65 9.36 106 9.1 105.22 Gly146 7.5 104.75 7.56 104.82
Asp66 9.96 124.06 10.01 124.4 Ser147 8.2 110.11 8.19 109.89
Phe67 6.62 116.04 6.69 116 Arg148
Thr68 7.28 109.02 7.25 108.73 Asn149
Arg69 8.65 122.09 8.68 122.05 Gly150 8.04 110.22 8.06 110.65
His70 6.53 111.11 Lys151 7.53 119.89 7.47 119.8
Asn71 7.49 112.49 7.44 112.24 Thr152 8.85 116.65 8.86 116.81
Gly72 9.66 110.6 9.67 111.25 Ser153 9.41 117.05 9.46 117.28
Thr73 7.93 112.2 7.86 109.83 Lys154 7.53 119.37 7.53 119.27
Gly74 8.71 114.04 8.8 114.03 Lys155 8.78 121.73 8.82 121.79
Gly75 8.11 109.15 8.06 108.9 Ile156 9.61 134.42 9.62 134.33
Lys76 6.97 115.71 6.93 115.5 Thr157 9.24 117.07 9.22 116.94
Ser77 7.79 114.41 7.75 114.44 Ile158 8.58 121.7 8.59 121.66
Ile78 8.55 111.24 8.55 111.1 Ala159 8.87 132.53 8.87 132.53
Tyr79 8.03 120.83 8.06 120.86 Asp160 8.06 111.55 8.06 111.51
Gly80 7.1 106.64 7.1 106.46 Cys161 8.58 116.13 8.59 116.09
Glu81 Gly162 6.84 104.18 6.84 104.04
Lys82 7.86 112.72 7.83 112.28 Gln163 9.05 121.01 9.08 121.11
Phe83 9.17 116.64 9.2 116.47 Leu164 8.59 126.15 8.59 125.92
Glu84 9.23 119.54 9.28 119.46 Glu165 8.13 126.36 8.12 126.08
Asp85 8.59 118.9 8.62 118.81
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Figure S1: Far-UV CD spectrum of CypA at 25◦C. The average CD signal from 16 scans is plotted at 1 nm intervals
between 190 nm and 240 nm.
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Figure S2: Fluorescence emission spectra of CypA with increasing CsA concentration. The key shows the concen-
tration ratio [CsA]/[CypA]. Emission spectra were recorded at 1 nm intervals between 300 nm and 400 nm with
excitation wavelength of 290 nm. The average emission value of three scans is plotted.
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Figure S3: (a) HSQC spectrum of unbound CypA. HSQC spectra are also shown at different time intervals following
initiation of HDX. These are (b) 53 minutes, (c) 113 minutes and (d) 4349 minutes.
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